47 results on '"Davis, John"'
Search Results
2. Brief Report: Rheumatoid Arthritis Is Associated With Left Ventricular Concentric Remodeling: Results of a Population-Based Cross-Sectional Study
3. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegenerʼs): Long-term followup of a multicenter longitudinal cohort
4. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis
5. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases
6. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis
7. Mortality in rheumatoid arthritis patients with heart failure: Comment on the article by Davis et al
8. Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
9. The Presentation and Outcome of Heart Failure in Patients With Rheumatoid Arthritis Differs From That in the General Population
10. Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegenerʼs Granulomatosis
11. Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis
12. The widening mortality gap between rheumatoid arthritis patients and the general population
13. Health-Related Quality of Life Outcomes in Patients With Active Ankylosing Spondylitis Treated With Adalimumab: Results From a Randomized Controlled Study
14. Six Refractory Lupus Patients Treated With Rituximab: A Case Series
15. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica
16. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study
17. Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
18. Solid Malignancies Among Patients in the Wegenerʼs Granulomatosis Etanercept Trial
19. Risk Factors For Functional Limitations in Patients With Long-Standing Ankylosing Spondylitis
20. Reductions in Health-Related Quality of Life in Patients With Ankylosing Spondylitis and Improvements With Etanercept Therapy
21. Damage Caused by Wegenerʼs Granulomatosis and Its Treatment: Prospective Data From the Wegenerʼs Granulomatosis Etanercept Trial (WGET)
22. A Serum Proteomic Approach to Gauging the State of Remission in Wegenerʼs Granulomatosis
23. Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America Recommendations for Conducting Clinical Trials in Ankylosing Spondylitis
24. Breaking the Ice: Testing Tumor Necrosis Factor α Blockade in Lupus
25. Results from an open-label extension study of etanercept in ankylosing spondylitis
26. Responsiveness and Discriminative Capacity of the Assessments in Ankylosing Spondylitis Disease-Controlling Antirheumatic Therapy Core Set and Other Outcome Measures in a Trial of Etanercept in Ankylosing Spondylitis
27. A brief history of Wegenerʼs granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegenerʼs granulomatosis Etanercept Trial Research Group
28. Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis: A Randomized, Controlled Trial
29. Treatment of Systemic Lupus Erythematosus–Associated Type B Insulin Resistance Syndrome With Cyclophosphamide and Mycophenolate Mofetil
30. Treatment of Systemic Lupus Erythematosus by Inhibition of T Cell Costimulation With Anti-CD154: A Randomized, Double-Blind, Placebo-Controlled Trial
31. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis
32. A Disease-Specific Activity Index for Wegener's Granulomatosis: Modification of the Birmingham Vasculitis Activity Score
33. MULTICENTRIC RETICULOHISTIOCYTOSIS: Case Report with Immunohistochemical Analysis and Literature Review
34. A PILOT STUDY OF 2-CHLORO-2′-DEOXYADENOSINE IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED GLOMERULONEPHRITIS
35. Accelerated aging influences cardiovascular disease risk in rheumatoid arthritis
36. Reply
37. Breaking the ice: Testing tumor necrosis factor ? blockade in lupus
38. Autoantibodies to Human Stress Proteins. A Survey of Various Rheumatic and Other Inflammatory Diseases
39. Effects of Glucocorticoids on Weight Change During the Treatment of Wegener's Granulomatosis.
40. Rheumatoid factor inhibition of in vitro binding of IgG complexes in the human glomerulus.
41. Interaction between rheumatoid factor and antibody/DNA COMPLEXES.
42. Cardiopulmonary Manifestations of Progressive Systemic Sclerosis.
43. Direct evidence for circulating dna/anti-dna complexes in systemic lupus erythematosus.
44. Anti-DNA antibody in procainmide-induced lupus erythematosus. Determination using DNA fractionated by methylated albumin-kieselguhr chromatography.
45. Acute Effects of Steroids On Immune Complex Profile of Patients with Systemic Lupus Erythematosus.
46. Age influences the clinical and serologic expression of systemic lupus erythematosus
47. Autoantibodies to nuclear antigens (ANA): Advances in laboratory tests and significance in systematic diseases. Second edition. Robert M. Nakamura, Carol L. Peebles, Robert L. Rubin, Daniel P. Molden, Eng M. Tan. Chicago, American Society of Clinical Pathologists Press, 1985. 163 pages. Illustrated. Indexed. $18.00
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.